louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06509399: Care Package for Preventing Pressure Ulcers in ICU Patients
Official title: Evaluation of the Effectiveness of a Pressure Ulcers Prevention Care Package in the Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pressure Ulcer
Nursing Caries
Keywords: Pressure ulcer
Care package
Intensive care unit
Evidence-based practice
Nursing
Lead sponsor: Abant Izzet Baysal University
Sponsor class: OTHER
First posted: 2024-07-19
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: experimental study randomised controlled
Primary purpose: PREVENTION

Brief summary: The aim of this study is to evaluate the effectiveness of the care package (CP) developed to prevent pressure injury (PI) in patients in intensive care and to evaluate the effect of the training given to nurses on their knowledge levels and attitudes.

Detailed description: This experimental study was carried out in the anesthesia and reanimation intensive care unit of Düzce Atatürk State Hospital. The part with patients was completed with a total of 72 patients, 36 in the control group and 36 in the application group. The occurrence rate of PI was compared between the control group and the application group. In the section about nurses, no sample was selected and all 50 nurses working in intensive care were included in the study. Nurses' knowledge and attitudes about PI before and after the training were compared. Data were analyzed using a statistical program.

Eligibility criteria: Inclusion Criteria:

* - 18 years of age or older,
* No development of pressure ulcers in any part of the body,
* Patients expected to stay in the clinic for at least 72 hours or more
* patients with a braden score below 15 points
* Obtaining written consent from the first-degree relatives of patients whose written consent is obtained, patients who are unconscious and unable to give consent

Exclusion Criteria:

* - 18 years of age or younger,
* BY in any part of the body,
* BBYRDS score more than 15
* Failure to give written consent by himself/herself or his/her 1st degree relative
* Exitus, discharge, change of department and the patient's wish to leave the study before completing the number of days determined during the data collection phase

Primary outcomes:
measure: Pressure Ulcer Formation
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Knowledge levels of nurses
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Bolu
country: Turkey
facility: Abant Izzet Baysal University Faculty of Health Science
state: Merkez
city: Bolu
country: Turkey
facility: Bolu Abant İzzet Baysal Üniversitesi/Sağlık Bilimleri Fakültesi
Study officials:
References:
Clinical trial NCT01419899: Increasing Viral Testing in the Emergency Department
Official title: Phase 2/3 Clinical Trial of the Effect of a Brief Intervention on Uptake of Rapid Testing for HIV and Hepatitis C Among Emergency Department Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Drug Use
HIV
Hepatitis C
Keywords: Brief intervention
Rapid testing
Lead sponsor: Rhode Island Hospital
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2011-08-18
Enrollment: 398
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine if a brief intervention delivered to emergency department patients increases the uptake of rapid HIV and hepatitis C testing in comparison to no brief intervention.


Eligibility criteria: Inclusion Criteria:

* Emergency department patient.
* Does not know HIV or hepatitis C status.
* Has an ASSIST V3 score that indicates recent illicit and/or prescription drug use.
* Fluency in English or Spanish.

Exclusion Criteria:

* Critically ill or injured.
* Homicidal and/or suicidal intention.
* Age \< 18 years or \> 64 years.
* Does not speak English or Spanish.

Primary outcomes:
measure: The agreement of the participant to be tested for HIV and hepatitis C
timeFrame: Within four hours of being consented into the study
Secondary outcomes:
measure: Identifying risky sexual behaviors of study participants
timeFrame: Within four hours of being consented into the study
Other outcomes:
Locations:
city: Providence
country: United States
facility: Rhode Island Hospital Emergency Department
state: Rhode Island
Study officials:
affiliation: Brown University
name: Roland C Merchant, MD, ScD
role: PRINCIPAL_INVESTIGATOR
affiliation: Brown University
name: Ted D Nirenberg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Merchant RC, Baird JR, Liu T, Taylor LE, Montague BT, Nirenberg TD. Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population. Acad Emerg Med. 2014 Jul;21(7):752-67. doi: 10.1111/acem.12419.
citation: Merchant RC, Baird JR, Liu T, Taylor LE. HCV among The Miriam Hospital and Rhode Island Hospital Adult ED Patients. R I Med J (2013). 2014 Jul 1;97(7):35-9.
citation: Bernardino VL, Baird JR, Liu T, Merchant RC. Comparison of substance-use prevalence among Rhode Island and The Miriam Hospital Emergency Department patients to state and national general population prevalence estimates. R I Med J (2013). 2014 Apr 1;98(4):30-4.
Clinical trial NCT02602899: Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy
Official title: Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Refractory Epilepsy
Keywords: PINS
Deep Brain Stimulator
Refractory Epilepsy
Anterior Thalamic Nucleus
Lead sponsor: Beijing Pins Medical Co., Ltd
Sponsor class: INDUSTRY
Collaborators: name: Beijing Tiantan Hospital
First posted: 2015-11-11
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluate the long-term clinical effectiveness and safety of the PINS Deep Brain Stimulation to patients with refractory epilepsy.


Eligibility criteria: Inclusion Criteria:

* age 12-60.
* having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal dose.
* at least 6 seizures per month.
* in good health except epilepsy.
* to with normal MMSE score
* patients or his(her) familys could understand this method and sign the informed consent 7）Patients with good compliance and could complete postoperative follow-up

Exclusion Criteria:

* results of MRI remind epilepsy caused by intracranial space-occupying lesions.
* the vagus nerve lesion and damage
* tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma，mental disease，peptic ulcer，diabetes Type 1，bad health etc, and other surgical contraindication.

Primary outcomes:
measure: Changes in seizure frequency from baseline to the seizure count evaluation period 6 month
timeFrame: 6 month of stimulation
Secondary outcomes:
measure: Changes in seizure frequency from baseline to the seizure count evaluation period
timeFrame: 1,3,6,12 months of stimulation
measure: Overall Quality of Life in Epilepsy-31 (QOLIE-31) Score in Patients With Baseline & at Least One Post-baseline QOLIE Assessment
timeFrame: Mean change from baseline QOLIE-31 Overall Score at 1,3,6,12 months
measure: Change in the Number of Anti-epileptic Drugs Prescribed
timeFrame: At 1,3,6,12 months
measure: Change from Baseline in the Engel and McHugh description
timeFrame: At 1,3,6,12 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tiantan Hospital
state: Beijing
Study officials:
affiliation: study principal investigator
name: Luming Li
role: STUDY_CHAIR
References:
Clinical trial NCT04309799: The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Meibomian Gland Function
Official title: The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Symptoms and Signs of Meibomian Gland Function
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Meibomian Gland Dysfunction
Keywords: Dry eye
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2020-03-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study plans to learn more about the effectiveness of the TearRestore eyelid warming mask on signs and symptoms of Meibomian Gland Dysfunction (MGD). MGD is a leading cause of dry eye symptoms. Warm compresses are a standard treatment recommended by physicians to treat those diagnosed with MGD. The study will investigate whether the TearRestore mask affects meibomian gland function and dry eye symptoms.

Detailed description: The study will evaluate the effectiveness of the TearRestore eyelid warming mask on signs and symptoms of MGD. Warm compress treatments have been recommended as part of the standard of care by eye physicians, and are an important means in treating MGD. However, current treatment options suffer from varied temperature maintenance and poor compliance. The TearRestore™ mask offers patients a unique experience through providing sustained heat and the ability to see throughout the treatment, which will improve efficacy through improved compliance. If shown to be effective in altering Meibomian gland secretions at a single visit, this novel treatment could potentially offer the millions of patients suffering from MGD a more convenient and effective way to treat the condition.

Eligibility criteria: Inclusion Criteria:

* Adult participants (age 18-89) of any race, gender or ethnicity, diagnosed with meibomian gland dysfunction
* Symptom score greater than eight on the SPEED questionnaire
* Less than 75nm lipid layer thickness (LLT) utilizing the Lipiview II
* Less than 10 second tear break up time (average of 3 measurements)

Exclusion Criteria:

* Participants with less than 6/15 meibomian glands yielding liquid secretions in either eyelid
* Diagnosed with a systemic autoimmune condition including but not limited to Sjogren's or Lupus

Primary outcomes:
measure: Standardized Patient Evaluation of Eye Dryness (SPEED) Questionnaire
timeFrame: Up to 60 days
Secondary outcomes:
measure: Lipid Layer Thickness
timeFrame: Up to 60 days
measure: Tear Breakup Time
timeFrame: Up to 60 days
measure: Number of Meibomian Glands Yielding Liquid Secretions
timeFrame: Up to 60 days
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado, Dept. of Ophthalmology
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Scott Hauswirth, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05477199: Physiotherapy in Post COVID-19 Syndrome Patients
Official title: Cognitive Behavioral Principles-based Treatment Program for Patients With Post COVID-19 Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post-COVID-19 Syndrome
Lead sponsor: Universidad de Granada
Sponsor class: OTHER
First posted: 2022-07-28
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients who have undergone COVID-19 infection often have long-term sequelae. One of the most prevalent sequelae is pain. The main objective of this research is to investigate the efficacy of a cognitive behavioral principles-based treatment program in fear avoidance beliefs, disability, pain catastrophizing and pain interference.


Eligibility criteria: Inclusion Criteria:

* Patients of both sexes.
* Agreed to participate.
* Post COVID-19 patients meeting the WHO definition for this disease.

Exclusion Criteria:

* Neurological or orthopaedic pathologies that limited voluntary movement.
* Cognitive impairment that prevented them from understanding and answering the questionnaires.
* Patients suffering from a reinfection with SARS-CoV-2.
* Patients who had been hospitalized due to COVID-19 infection.
* Patients who had pre-existing chronic pain according to the current IASP definition.

Primary outcomes:
measure: Fear-avoidance belief changes
timeFrame: Baseline
measure: Fear-avoidance belief changes
timeFrame: At 6 weeks at the end of the intervention
Secondary outcomes:
measure: Changes in functionality
timeFrame: Baseline
measure: Changes in functionality
timeFrame: At 6 weeks at the end of the intervention
measure: Changes in pain catastrophizing
timeFrame: Baseline
measure: Changes in pain catastrophizing
timeFrame: At 6 weeks at the end of the intervention
measure: Changes in pain interference
timeFrame: Baseline
measure: Changes in pain interference
timeFrame: At 6 weeks at the end of the intervention
measure: Changes in the sensory, affective and evaluative dimensions of pain.
timeFrame: Baseline
measure: Changes in the sensory, affective and evaluative dimensions of pain.
timeFrame: At 6 weeks at the end of the intervention
Other outcomes:
Locations:
city: Granada.
country: Spain
facility: Faculty of Health Sciences. University of Granada.
state: Granada
Study officials:
affiliation: Universidad de Granada
name: Marie Carmen Valenza, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01508299: Skin Prick Test for the Diagnosis of Food Allergy- a Comparison of Different Commercial Extracts and Raw Food
Official title: Skin Prick Test for the Diagnosis of Food Allergy- a Comparison of Different Commercial Extracts and Raw Food
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Allergy
Keywords: skin test
raw food
commercial extract
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2012-01-11
Enrollment: 200
Sex: ALL
Minimum age (years): 1
Maximum age (years): 120
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Immediate food allergy is , sometimes , a life threatening situation . Diagnosis is done by skin prick test with commercial extracts. Nevertheless, some of the extracts are not optimal and reproduce false negative results (no allergy) in patients with history highly suggestive of allergic reaction. The aim of this study is to compare the reproducibility of different commercial extracts and raw food in patients with convincing history of acute allergic symptoms related to food .


Eligibility criteria: Inclusion Criteria:

* Suspected immediate allergic reaction to food

Exclusion Criteria:none

Primary outcomes:
measure: correlation between the results of skin test with commercial extracts and raw food
timeFrame: immediate
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar-Saba
country: Israel
facility: Allergy and clinical immunology unit , Meir hospital
Study officials:
References:
Clinical trial NCT01211899: 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
Official title: Incidence and Prognosis of Disseminated Intravscular Coagulation in Patients Severe Sepsis and Septic Shock; Association With 4G/5G Polymorphism of PAI-1 Gene
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Severe Sepsis
Keywords: polymorphism,
plasminogen activator inhibitor,
disseminated intravascular coagulation,
Lead sponsor: Hallym University Medical Center
Sponsor class: OTHER
First posted: 2010-09-30
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to the ICU for severe sepsis or septic shock

Brief summary: Data on 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene are limited in Asian patients with sepsis. Therefore, the investigators aim to prospectively investigate the incidence of 4G/5G polymorphism and its relationship with disseminated intravascluar coagulatin in patients with severe sepsis and septic shock.


Eligibility criteria: Inclusion Criteria:

* Adult patinents aged \> 18 years, Patients satisfying the criteria by 2008 Surviving Sepsis Campagin, Patients who are determined as having a sepsis within 24 hours of ICU stay

Exclusion Criteria:

* Do-not-resuscitate, cardiopulmonary resuscitation, ICU stay \< 1 day, Refusal to participate in the study, Hematologic malignancy or liver cirrhosis (Child C), Congenital abnormality in coagulation system, Transfer from other ICUs or hospitals

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02927899: Taste Acceptability of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer
Official title: Acceptability in the Taste of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Carcinoma
Keywords: Tomato-Soy-Arugula
Lead sponsor: Ohio State University Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2016-10-07
Enrollment: 27
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study is a sensory analysis of several different formulations of a novel tomato-soy-arugula seed beverage in men with prostate cancer. Eating a diet rich in a variety of fruits and vegetables has been associated with decreased risk of a variety of diseases, including prostate cancer. Mixed vegetable beverages may be useful in prostate cancer survivorship.

Detailed description: PRIMARY OBJECTIVES:

I. To evaluate the sensory acceptability of a novel tomato-soy-arugula seed beverage in men with prostate cancer.

OUTLINE:

Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.

Eligibility criteria: Inclusion Criteria:

* Have a prostate cancer diagnosis
* Not be allergic to tomato or tomato products
* Not be allergic to soy or soy related products
* Not be allergic to any cruciferous vegetables (e.g.: broccoli, cauliflower, kale, brussels sprouts, arugula/rocket, bok choy, etc.)
* Voluntarily agree to participate and read the informed consent documents

Primary outcomes:
measure: Sensory acceptability of tomato-soy-arugula seed beverages assessed by survey
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Ohio State University Comprehensive Cancer Center
state: Ohio
Study officials:
affiliation: Ohio State University Comprehensive Cancer Center
name: Steven Clinton, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05690399: Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer
Official title: Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer in 2 Centers in Asyut
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prostate Cancer
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-01-19
Enrollment: 100
Sex: MALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy

- Newly diagnosed/ metastatic at presentation

Brief summary: To evaluate clinical and pathological characteristics and treatment protocol and outcomes of patients with prostate cancer in 2 centers of Asyut from 2013 to 2023

Detailed description: Inclusion criteria :

* Male patient , Age ≥ 40 yo
* Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy in South Egypt Cancer Institute "SECI" \& Asyut clinical oncology department
* Newly diagnosed/ metastatic at presentation
* ECOG 0-4

  • Exclusion criteria:
* Having Other types of malignancy.

Eligibility criteria: Inclusion Criteria:

* Male patient , Age ≥ 40 yo
* Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy
* Newly diagnosed/ metastatic at presentation
* ECOG 0-4

Exclusion Criteria:

* Having Other types of malignancy.

Primary outcomes:
measure: Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Assiut University
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03966599: Comparison of Hemodynamic Stability and Pain Control
Official title: Comparison of Hemodynamic Stability and Pain Control Between Two Anesthesia Positions of Lateral and Prone in Patients Undergoing Percutaneous Nephrolithotomy; a Randomized Controlled Trial Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Percutaneous Nephrolithotomy
Keywords: Percutaneous Nephrolithotomy
Analgesic
hemodynamic status
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2019-05-29
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study was designed to evaluate whether patient position (lateral vs. prone) has affect on the need for analgesia and onset of pain after surgery.

Detailed description: Percutaneous Nephrolithotomy is the preferred surgical treatment in many cases of kidney stones which is performed in different positions such as prone, lateral, and supine. However, we do not have enough evidence comparing prone and lateral positioning regarding the need for analgesia and onset of pain after surgery. This study was designed to evaluate whether patient position (lateral vs. prone) has affect on the need for analgesia and onset of pain after surgery.

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria were age between 18-65 years,
* having kidney stones; consent for spinal anesthesia,
* ASA classes (American Society of Anesthesiologists class) of 1 and 2 (patients without any cardiovascular or respiratory disorders)
* superior and median ureter larger than 20 mm in diameter.

Exclusion Criteria:

* those with coagulation defects,
* severe pain requiring more than one dose of fentanyl,
* considerable rise of blood pressure or heart rate during the operation.

Primary outcomes:
measure: pain intensity in VAS score and need for analgesics in milligram
timeFrame: at one year after surgery
Secondary outcomes:
measure: hemodynamic state
timeFrame: at one year after surgery
Other outcomes:
Locations:
Study officials:
affiliation: shahid beheshti university of medical sciences, tehran, iran
name: Hamidreza Shemshaki, MD
role: STUDY_DIRECTOR
References: